Study population
atrial fibrillation, coronary artery disease, hepatorenal dysfunction
ATRIAL FIBRILLATION, HEART, CORONARY ARTERY DISEASE, CIRCULATORY ARREST
This study is an investigator-initiated, single center, single-blind, randomized, placebo-controlled clinical trial. It was initiated in November 2020 and completed in August 2022 after receiving approval from the ethical committee of Nanjing Drum Tower Hospital (2020-293-02) and registered in the Chinese Clinical Trial Registry (ChiCTR2000040129). The study enrolled 132 patients with CPB from the department of cardiothoracic in Nanjing Drum Tower Hospital. Written informed consent was obtained from all patients before enrollment. Patients were randomized in a 1:1 ratio to receive either colchicine 0.5 mg once daily or placebo for 3 days before the operation and for 5 days after operation. The design of the trial has been published previously [The inclusion criteria were as follows: Adult patients undergoing on-pump cardiovascular surgery, aged 50–75 (including 50 and 75), male or female, have signed the informed consent form (ICF); patients with New York Heart Association Class (NYHA): I-II.The “low-risk” patients were enrolled in our study based on following exclusion criteria: patients undergoing emergency surgery; patients undergoing deep hypothermic circulatory arrest surgery; patients with atrial fibrillation who need radiofrequency catheter ablation; with coronary artery disease who need percutaneous transluminal coronary intervention or CABG; poor hepatorenal dysfunction (Child Pugh Class B or C, estimated glomerular filtration rate < 35 mL/min/1.73 m